---
title: "Polatuzumab vedotin"
slug: "polatuzumab-appealed"
date: "2024-01-23"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[Antibody Drug Conjugates]]

# Polatuzumab vedotin

- Mechanism:
  - Anti-CD79b humanized IgG1;
  - after binding,
    - releases antimicrotubule agent MMAE,
    - producing cell cycle arrest & apoptosis
- Approved indication: [[Diffuse large B-cell lymphoma]]
- Dosing:
  - 1.8 mg/kg IV every 21 d;
  - avoid use in mod./sev. hepatic impairment;
  - no adjustment for mild/mod. renal impairment;
  - manufacturer-recommended dose reductions available for hematologic toxicity, neuropathy
- PK/PD:
  - T1/2 12 d for ADC, 4 d for MMAE;
  - MMAE metabolized hepatically (CYP3A4)
- AEs:
  - Myelosuppression,
  - neuropathy,
  - diarrhea,
  - low emetogenicity,
  - infusion rxns,
  - infxns
- DDI:
  - Strong CYP3A4 inhibitors/inducers likely increase/decrease MMAE exposure;
  - no specific dose adjustments recommended;
  - MMAE is a P-glycoprotein substrate
- Clinical pearls:
  - HSV/VZV & PJP prophylaxis required,
  - consider 1Â° GCSF prophylaxis
